Joint Corp (NASDAQ:JYNT) – Stock analysts at B. Riley issued their Q2 2020 earnings per share (EPS) estimates for shares of Joint in a note issued to investors on Tuesday, November 5th. B. Riley analyst J. Van. Sinderen anticipates that the company will post earnings of $0.05 per share for the quarter. B. Riley currently has a “Buy” rating and a $23.00 target price on the stock. B. Riley also issued estimates for Joint’s Q3 2020 earnings at $0.06 EPS.
Joint (NASDAQ:JYNT) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.03 by $0.01. Joint had a return on equity of 114.93% and a net margin of 5.38%. The firm had revenue of $12.73 million during the quarter, compared to analysts’ expectations of $11.60 million.
Several other research firms have also recently commented on JYNT. DA Davidson reaffirmed a “buy” rating on shares of Joint in a report on Monday. Lake Street Capital increased their price target on Joint from $20.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. TheStreet cut Joint from a “b-” rating to a “c” rating in a report on Tuesday, September 3rd. Maxim Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Joint in a report on Friday, August 9th. Finally, Zacks Investment Research raised Joint from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a report on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $24.17.
Shares of NASDAQ:JYNT traded down $0.66 during midday trading on Friday, hitting $19.15. The company had a trading volume of 459,700 shares, compared to its average volume of 155,324. Joint has a twelve month low of $6.51 and a twelve month high of $21.80. The company has a debt-to-equity ratio of 3.33, a current ratio of 1.04 and a quick ratio of 1.04. The stock has a market cap of $275.64 million, a price-to-earnings ratio of 478.75 and a beta of 1.01. The business’s 50-day simple moving average is $18.82 and its 200-day simple moving average is $18.09.
Hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its stake in Joint by 1,199.3% during the second quarter. Tower Research Capital LLC TRC now owns 1,767 shares of the company’s stock worth $32,000 after acquiring an additional 1,631 shares during the last quarter. Winslow Evans & Crocker Inc. acquired a new stake in Joint during the third quarter worth $36,000. Marshall Wace North America L.P. acquired a new stake in Joint during the first quarter worth $47,000. Strs Ohio acquired a new stake in Joint during the second quarter worth $63,000. Finally, Tower Research Capital LLC TRC increased its stake in Joint by 100.7% during the third quarter. Tower Research Capital LLC TRC now owns 3,547 shares of the company’s stock worth $66,000 after acquiring an additional 1,780 shares during the last quarter. 64.45% of the stock is owned by institutional investors.
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Read More: Return on Investment (ROI)
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.